"The longer it takes breast cancer to metastasise, the more aggressive it becomes"
"El Periódico" and other media, report on a recent study that reveals the biological changes in breast cancer between the primary tumour and metastasis.
Published in the journal Cancer Research, this work describes for the first time that the longer the time between the diagnosis of the primary tumour and the onset of metastasis is, the more aggressive the cancer becomes.
The first author of the study is Juan Miguel Cejalvo, PhD student of the PhD4MD programme led by Aleix Prat at IDIBAPS and ICREA researcher Roger Gomis at IRB Barcelona.
Link to El Periódico
Other media
Link to CCMA.cat
Link to 20minutos.es
Link to Diario de Córdoba
Link to Revista IM Médico
Related content
News
These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.
Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.
The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
